Comparative Pharmacology
Head-to-head clinical analysis: METHOTREXATE PRESERVATIVE FREE versus OTREXUP PFS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: METHOTREXATE PRESERVATIVE FREE versus OTREXUP PFS.
METHOTREXATE PRESERVATIVE FREE vs OTREXUP PFS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methotrexate is a folate analog that inhibits dihydrofolate reductase (DHFR), blocking the conversion of dihydrofolate to tetrahydrofolate, thereby inhibiting thymidylate and purine synthesis, leading to impaired DNA synthesis, repair, and cellular replication. It also exhibits immunomodulatory and anti-inflammatory effects through adenosine-mediated pathways.
Methotrexate is a folate analog that inhibits dihydrofolate reductase, thereby blocking the synthesis of purines and pyrimidines, leading to inhibition of DNA synthesis and cell proliferation. It also has immunosuppressive and anti-inflammatory effects through modulation of adenosine pathways and cytokine release.
Rheumatoid arthritis: 7.5 mg orally once weekly. Psoriasis: 10-25 mg orally once weekly. Neoplastic diseases: IV or IM 30-40 mg/m² once weekly, or oral 2.5-5 mg every 12 hours for 3 doses once weekly. Intrathecal: 12 mg/m² (maximum 15 mg) every 2-7 days.
Methotrexate 7.5-15 mg subcutaneously once weekly. For rheumatoid arthritis, start at 7.5 mg weekly, titrate to 20-25 mg weekly as tolerated.
None Documented
None Documented
Terminal elimination half-life is 3-10 hours for low doses (≤50 mg/m²) and 8-15 hours for high doses (>1 g/m²); prolonged to 24-48 hours in patients with third-space effusions or renal impairment.
5-8 hours (low-dose methotrexate); 8-15 hours (high-dose). Prolonged in renal impairment, third-space effusions, or concomitant NSAIDs.
Renal excretion (80-90% as unchanged drug via glomerular filtration and active tubular secretion; enterohepatic recirculation occurs; fecal elimination <10%).
Renal excretion (80-90% unchanged) via glomerular filtration and tubular secretion; biliary/fecal elimination accounts for <10%.
Category D/X
Category C
Antimetabolite
Antimetabolite